Overview

• Alector Q3 2025 revenue beats analyst expectations despite a year-over-year decline

• Net loss for Q3 2025 narrows compared to the same period last year

• Company implements 47% workforce reduction to focus on high-priority programs

Outlook

• Company anticipates collaboration revenue between $13 mln and $18 mln for 2025

• Alector targets IND filing for AL137 in 2026

• Independent interim analysis for PROGRESS-AD trial planned for 1H 2026

Result Drivers

• ABC PLATFORM - Alector's focus on its proprietary Alector Brain Carrier platform is driving innovation in neurodegenerative disease therapies, per CEO Arnon Rosenthal

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Alector Inc is $1.50, about 16.3% above its November 5 closing price of $1.26

Press Release: ID:nGNX3cm25w

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)